Benzinga's Daily Biotech Pulse: Achaogen Slumps On Mixed FDA Panel Vote, Pacific Biosciences Sinks On Q1 Miss
Shanthi Rexaline , Benzinga Staff Writer
May 03, 2018 8:31am 663 Comments
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling the Peaks
(Stocks hitting 52-week highs on May 2)
CASI Pharmaceuticals Inc (NASDAQ: CASI)
Eleven Biotherapeutics Inc (NASDAQ: EBIO)
Enanta Pharmaceuticals Inc (NASDAQ: ENTA)
Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA)
MORPHOSYS AG/S ADR (NASDAQ: MOR) reported Q1 results after the close)
SIGA Technologies, Inc. (NASDAQ: SIGA) (FDA panel backed its small pox treatment candidate)
Sophiris Bio Inc (NASDAQ: SPHS)
Surface Oncology, Inc. (NASDAQ: SURF)
Down In The Dumps
(Stocks hitting 52-week lows on May 2)
Orgenesis Inc (NASDAQ: ORGS)
THERAPIX BIOSCI/S ADR (NASDAQ: TRPX)
Stocks In Focus
Exelixis Gains On Q1 Beat, Collaboration Agreement
Exelixis, Inc. (NASDAQ: EXEL) reported Q1 EPS of 37 cents on revenues of $212.3 million, beating expectations.
The company also announced a collaboration with biologics company Invenra to develop multi-specific antibodies for treating cancer, which will provide the former exclusive worldwide rights to one pre-clinical asset.
Exelixis will pay Invenra an upfront payment of $2 million, plus $2 million at the initiation of each of the six additional discovery projects for which it is to collaborate with Invenra, potential developmental milestone payments up to $131.5 million, and global milestone payments up to $325 million on achievement of certain sales targets.
The stock was up 6 percent to $21.90 Thursday morning.
Achaogen's Slumps On Mixed FDA Panel Vote
Achaogen Inc (NASDAQ: AKAO) shares slumped 28 percent after the FDA's Antimicrobial Drugs Advisory Committee voted 11 to 4 that the company didn't provide substantial evidence of safety and effectiveness of its plazomicin to treat bloodstream infections in patients with limited or no treatment options. However, the panel voted 15 to 0 in favor of plazimicin's safety and effectiveness of complicated urinary tract infection.
The PDUFA action date is set for June 25, 2018.
Pacific Biosciences' Q1 Miss
Pacific Biosciences of California (NASDAQ: PACB) reported a Q1 loss of 20 cents per share, wider than the 19 cents loss expected by analysts. Revenues fell about 9 percent to $16.28 million and trailed the $24.54 million consensus estimate.
The stock shed 17.5 percent to $2.21 after hours.
See Also: Attention Biotech Investors: Mark Your Calendar For These May PDUFA Action Dates
Hologic Lowers FY18 Revenue Guidance
Hologic, Inc. (NASDAQ: HOLX)'S Q1 non-GAAP loss per share widened to 53 cents from 50 cents a year ago. Revenues, however, rose 10.3 percent to $789.3 percent. Analysts estimated a loss of 53 cents per share on revenues of $781.84 million.
Citing lower-than-expected sales of Cynosure, the medical aesthetic technology company it acquired last year, Hologic lowered its FY18 revenue guidance but reiterated its non-GAAP EPS guidance.
The following companies report earnings on Thursday:
ABIOMED, Inc. (NASDAQ: ABMD) Q4 EPS $0.80 Beats $0.64 Estimate, Sales $174.436M Beat $164.31M Estimate
Adamas Pharmaceuticals Inc (NASDAQ: ADMS)
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)
AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) Q1 EPS $(1.59) Misses $(0.54) Estimate, Sales $146.356M Miss $151.79M Estimate
Arbutus Biopharma Corp (NASDAQ: ABUS)
Editas Medicine Inc (NASDAQ: EDIT)
G1 Therapeutics Inc (NASDAQ: GTHX)
Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) Q1 EPS $(0.40) Beats $(0.43) Estimate, Sales $25.21 Miss $22.96M Estimate
Pacira Pharmaceuticals Inc (NASDAQ: PCRX) Q1 EPS $0.02 Beats $0.01 Estimate, Sales $74.607M Beat $73.93M Estimate
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) Q1 EPS $4.67 Beats $4.32 Estimate, Sales $1.511B Beat $1.51B Estimate
Sarepta Therapeutics Inc (NASDAQ: SRPT)
Adcom Schedule
A joint meeting of the Gastrointestinal Drugs Advisory Committee and the Pediatric Advisory Committee is scheduled for May 3 to discuss Mallinckrodt PLC (NYSE: MNK) unit InfaCare Pharma's NDA for stannsoporfin injection, intramuscular formulation. The pipeline candidate is being tested for treating neonates greater than or equal to 35 weeks of gestational age with indicators of hemolysis who are at risk of developing severe hyperbilirubinemia.
UNITY Biotech announced it has priced its initial public offering, or IPO, of 5 million shares at $17 per share. The company said shares would begin to trade on the Nasdaq on Thursday under the ticker symbol UBX.
Medical technology company Inspire Medical Systems priced its IPO of 6.75 million shared at $16 per share. Shares are due to be listed on the NYSE under the ticker symbol INSP, and will begin to trade on Thursday.
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Related Articles (IBB + AKAO)
The Week Ahead In Biotech: FDA To Issue Decisions On Merck And Aurinia Drug Applications
The Daily Biotech Pulse: Alexion Pauses COVID-19 Study, NantKwest Readout, Organogenesis Jumps On Guidance, Trial Updates
The Daily Biotech Pulse: Bausch Health Issues Positive Pre-Announcement, Acorda Streamlines Operations
The Daily Biotech Pulse: GSK, Vir To Start COVID-19 Antibody Study, Novartis In-Licenses BeiGene's Cancer Drug, Earnings Preannouncements Continue
The Week Ahead In Biotech (Jan 10-16): Expect Stocks To Move As J.P. Morgan Healthcare Conference Kicks Off
The Daily Biotech Pulse: Sarepta Gene Therapy Study Readout, Novavax Vaccine Supply Deal, 2 IPOs
Posted-In: Biotech Earnings News FDA Trading Ideas Best of Benzinga
Need earnings data?
2 MP, AMZN: Investors Want A Chamath Palihapitiya ETF And They Might Get It Soon
3 PG, AMZN: Barron's Picks And Pans: Exxon Mobil, GameStop, Int...
4 TSLA: Elon Musk Talks About Tesla's Inspiration For B...
5 GEVO, DTIL: 33 Stocks Moving in Tuesday's Pre-Mar...
6 BYDDF, NIO: Tesla Begins Model Y SUV Deliver...
7 TSLA: Elon Musk Donates $5M To Onl...
1 CMC: Understanding Commercial Metals's Ex-Dividend Date
2 LTC: Ex-Dividend Date Insight: LTC Properties
3 THQ: Analyzing Tekla Healthcare Opps's Ex-Dividend Date
4 THW: Ex-Dividend Date Insight: Tekla World Healthcare
5 MOV: Ex-Dividend Date Insight: Movado Group
6 ARDC: Understanding Ares Dynamic Credit's Ex-Dividend Date
7 BGH: Analyzing Barings Global Short's Ex-Dividend Date